These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37481830)

  • 1. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation.
    Li X; Kalwak K; Beier R; Kehne J; Möller AK; Baumgart J; Beelen DW; Hilger RA; Vora A; Sykora KW
    Drug Metab Pharmacokinet; 2023 Oct; 52():100515. PubMed ID: 37481830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
    Romański M; Wachowiak J; Główka FK
    Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
    Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
    Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
    Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
    Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
    Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
    Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
    Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
    Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
    Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
    ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
    Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
    Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
    van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
    Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
    Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
    Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.